Cover Page

Cite item


Background: Essential arterial hypertension is one of the most common causes of chronic kidney disease. Timely identification of asymptomatic chronic kidney disease may help to prevent development of renal failure and maintain kidney functioning. Aim: To assess changes in renal function parameters in patients with arterial hypertension and abdominal obesity with a  history of a stroke, depending on the target levels of systolic blood pressure (SBP) during the recovery period of stroke. Materials and methods: We assessed 88 patients with arterial hypertension with a  history of an acute cerebrovascular accident within the last 1 to 6 months (mean age, 58.8±9.5 years). During 2 to 4 weeks of their hospital stay, their antihypertensive treatments were titrated to reach the chosen target levels of blood pressure. Thereafter, the patients were followed up for 8 to 12 months with baseline and follow-up measurements of their antropometric and clinical chemistry parameters including blood urea nitrogen and serum creatinine and estimated glomerular filtration rate (CKD-EPI). Chronic kidney disease was diagnosed by albumin and creatinine measurements with calculation of albumin/creatinine ratio in the morning urine portion. Results: There was a  positive correlation between office SBP and serum creatinine (r=0.5, р=0.01), serum albumin (r=0.4, р=0.003) and creatinine in the morning urine portion (r=0,5, р=0.0001). Hip circumference negatively correlated with serum creatinine and albumin/creatinine ration at the end of the follow-up (r=-0.3, р=0.04 and r=-0.3, р=0.04, respectively). Bodyweight correlated positively with the glomerular filtration rate (r=0.3, р=0.04), whereas waist to hip ration correlated with urine albumin at the end of the follow-up (r=0.3, р=0.01). Multiple regression analysis showed an association between mean office SBP and serum creatinine (β=0.43, р=0.04), urine albumin (β=0.33, р=0.02) and urine creatinine level (β=0.39, р=0.005). Conclusion: We found an association between SBP and renal function. SBP levels below 135 mm Hg are associated with an improvement of the renal function, whereas SBP levels below 124 mm Hg are associated with a significant decrease in renal function assessed by glomerular filtration rate and albumin/creatinine ratio. The efficacy of antihypertensive treatment in the recovery period after an acute cerebrovascular accident should be assessed with consideration of renal function measured by glomerular filtration rate and microalbuminuria levels. 

About the authors

E. A. Lopina

Orenburg State Medical University;
Clinical City Hospital 1

Author for correspondence.

Postgraduate Student, Chair of Hospital Therapy

6 Sovetskaya ul., Orenburg, 460000

23 Gagarina prospect, Orenburg, 460040

Tel.: +7 (3532) 35 70 15

Russian Federation


  1. Кобалава ЖД, Виллевальде СВ, Ефремовцева МА. Основы кардиоренальной медицины. М.: ГЭОТАР-Медиа; 2014. 256 с.
  2. Мухин НА, Моисеев ВС, Моисеев СВ, Фомин ВВ, Кобалава ЖД. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Терапевтический архив. 2004;76(6):39–46.
  3. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW; American Heart Association Kidney and Cardiovascular Disease Council; Council on High Blood Pressure Research; Council on Cardiovascular Disease in the Young; Council on Epidemiology and Prevention; Quality of Care and Outcomes Research Interdisciplinary Working Group. Detection of chronic kidney dis￾ease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114(10):1083–7. doi: 10.1161/CIRCULATIONAHA.106.177321.
  4. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens. 2004;17(10):986–93. doi: 10.1016/j.amjhyper.2004.08.010.
  5. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002;16(2):79–89. doi: 10.1038/sj/jhh/1001316.
  6. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract. 2008;62(1):97–108. doi: 10.1111/j.1742- 1241.2007.01620.x.
  7. Моисеев CВ, Фомин ВВ, Сагинова ЕА. Исследование HOPE: накопленный опыт – в по- вседневную практику. Клиническая нефрология. 2009;(3):73–8.
  8. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и НОНР. Кардиоваскулярная терапия и профилактика. 2008;7(6 Прил. 3).
  9. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Рекомендации комитета экспертов Российского кардиологического общества, Научного общества нефрологов России, Российской ассоциации эндокринологов, Российского медицинского общества по артериальной гипертонии, Национального общества по изучению атеросклероза, Российского научного медицинского общества терапевтов. Российский кардиологический журнал. 2014;(8): 7–37.
  10. Бугрова СА. Метаболический синдром. В: Дедов ИИ, Мельниченко ГА, ред. Ожирение. М.: МИА; 2004. с. 44–79.
  11. Чазова ИЕ, Ратова ЛГ, Бойцов СА, Небиеридзе ДВ. Диагностика и лечение артериальной гипертензии (Рекомендации российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;(3):5–26.
  12. Смирнов АВ, Шилов ЕМ, Добронравов ВА, Каюков ИГ, Бобкова ИН, Швецов МЮ, Цыгин АН, Шутов АМ. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012;16(1):89–115.
  13. Kidney Disease: Improving Global Outcomes. CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
  14. Либис РА, Исаева ЕН. Возможность применения индекса висцерального ожирения в диагностике метаболического синдрома и прогнозировании риска его осложнений. Российский кардиологический журнал. 2014;(9):48–53.
  15. Mimran A, Ribstein J. Microalbuminuria in essential hypertension. Clin Exp Hypertens. 1993;15(6):1061–7.

Copyright (c) 2016 Lopina E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies